Focus: Drugmakers pressured with Trump tariffs after price‑cut talks faltered

Core Viewpoint - U.S. President Donald Trump's threat to impose 100% tariffs on branded drugs has increased pressure on pharmaceutical companies to negotiate price cuts and relocate manufacturing operations after previous discussions failed earlier this year [1] Group 1 - The potential 100% tariffs on branded drugs could significantly impact the pharmaceutical industry, prompting companies to reconsider their pricing strategies [1] - Industry lobbyists and executives indicate that the threat of tariffs is a critical factor influencing negotiations between pharmaceutical companies and the government [1] - The failure of earlier talks has led to heightened urgency among pharmaceutical companies to reach agreements on pricing and manufacturing adjustments [1]